Thursday, October 1, 2026

Neovii appoints Duncan Ferguson as Chief Commercial Officer

Neovii Pharmaceuticals AG has named Duncan Ferguson as Chief Commercial Officer, effective 1 September 2026. In the role, he will lead the company’s global commercial strategy and support the international expansion of its transplantation franchise.

The Rapperswil-based company is linking the appointment to its broader growth plans. Ferguson will focus on established and emerging markets, strategic partnerships and the further development of Neovii’s commercial capabilities worldwide.

Commercial background across global pharma markets

According to Neovii, Ferguson brings nearly three decades of commercial leadership experience across specialty pharmaceuticals, rare diseases, immunology, oncology and neuroscience.

He most recently served as Vice President Commercial at Essential Pharma. His responsibilities there included sales, marketing, market access and partnered markets across regions including Europe, the Middle East, Latin America and Asia.

Earlier in his career, Ferguson held senior commercial roles at Jazz Pharmaceuticals, Aspen Pharmacare, LEO Pharma and Abbott Laboratories. Neovii points to his track record in building international commercial organisations and supporting market expansion for innovative therapies.

Role in transplantation and future pipeline planning

As CCO, Ferguson joins Neovii’s Executive Leadership Team and will report directly to CEO Frédéric Prince. His remit includes sustainable growth, stronger global partnerships and the continued enhancement of commercial operations.

He will also contribute to commercial strategy for future pipeline opportunities in immune-mediated diseases. This includes preparations related to Neovii’s ongoing Phase 2 GIRO study in Type 1 Diabetes.

Prince said Ferguson’s experience in international specialty pharma businesses will support Neovii’s next stage of growth. Ferguson highlighted the company’s transplantation position and its potential to broaden its impact in immune-mediated diseases.